Table 2.
Presenting Clinical Characteristics
| Overall (n = 323) | SA IE (n = 85) | NSA IE (n = 238) | p - Value | |
|---|---|---|---|---|
| NYHA Class | 0.146 | |||
| Class 1 & 2 | 264 (81.7) | 65 (76.5) | 199 (83.6) | |
| Class 3 & 4 | 59 (18.3) | 20 (23.5) | 39 (16.4) | |
| Fever, n (%) | 194 (60.1) | 60 (70.6) | 134 (56.3) | 0.021 |
| Angina, n (%) | 49 (15.2) | 12 (14.1) | 37 (15.6) | 0.753 |
| eGFR, (ml/min) | 63.3 ± 33.6 | 58.9 ± 34.7 | 64.9 ± 33.2 | 0.161 |
| < 60 | 153 (47.4) | 46 (54.1) | 107 (45.0) | |
| ≥ 60 | 170 (52.6) | 39 (45.9) | 131 (55.0) | |
| Vascular complications | 143 (44.6) | 50 (58.8) | 93 (39.4) | 0.002 |
| Immunological phenomenon | 65 (20.2) | 19 (22.4) | 46 (19.4) | 0.562 |
| New or worsening CHF | 101 (31.3) | 22 (25.9) | 79 (33.2) | 0.212 |
| Persistent bacteremia | 76 (23.6) | 32 (37.7) | 44 (18.6) | 0.000 |
| Leukocytosis | 144 (44.6) | 41 (48.2) | 103 (43.3) | 0.430 |
| Pre-op septic shock, n (%) | 53 (16.4) | 20 (23.5) | 33 (13.9) | 0.039 |
| Pre-op embolic event, n (%) | 77 (24.0) | 28 (33.3) | 49 (20.7) | 0.020 |
| Pre-op stroke, n (%) | 55 (17.0) | 23 (27.1) | 32 (13.5) | 0.004 |
| Pre-op MI, n (%) | 29 (9.0) | 8 (9.4) | 21 (8.8) | 0.871 |
| Staph Aureus Species | ||||
| MRSA | 21 (24.7) | |||
| MSSA | 64 (75.3) | |||
| Prosthetic Valve Endocarditis | 109 (33.7) | 29 (34.1) | 80 (33.6) | |
| Affected Valves | ||||
| Aortic valve | 206 (63.8) | 42 (49.4) | 164 (68.9) | 0.001 |
| Mitral valve | 192 (59.4) | 56 (65.9) | 136 (57.1) | 0.159 |
| Tricuspid valve | 27 (8.4) | 10 (11.8) | 17 (7.1) | 0.186 |
Values are means ± SD, or counts (%). NYHA New York Heart Association Class, GFR Glomerula Filtration Rate, CHF Congestive Heart Failure, MI Myocardial Infarction, MRSA Methicillin Resistant Staph Aureus, MSSA Methicillin Sensitive Staph Aureus